Identification of novel macrolides with antibacterial, anti-inflammatory and type I and III IFN-augmenting activity in airway epithelium

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 10, 2016, Pages 2767-2781

  Porter, James D ^a,b   Watson, Jennifer ^a   Roberts, Lee R ^c   Gill, Simren K ^d   Groves, Helen ^d   Dhariwal, Jaideep ^a,b   Almond, Mark H ^a,b   Wong, Ernie ^a,b   Walton, Ross P ^a,b   Jones, Lyn H ^c   Tregoning, John ^d   Kilty, Iain ^c   Johnston, Sebastian L ^a,b   Edwards, Michael R ^a,b  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c PFIZER INC   (United States)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; BETA INTERFERON; BIOLOGICAL FACTOR; CYTOKINE; ERYTHROMYCIN; INTERFERON; MAC122; MAC132; MAC14; MAC153; MAC162; MAC183; MAC185; MAC2; MAC202; MAC206; MAC39; MAC5; MAC51; MACROLIDE; MESSENGER RNA; MYXOVIRUS RESISTANCE PROTEIN A; NUCLEIC ACID BINDING PROTEIN; OLEANDOMYCIN DERIVATIVE; TYPE III INTERFERON; TYPE III INTERFERON LAMBDA 1; TYPE III INTERFERON LAMBDA 2; TYPE III INTERFERON LAMBDA 3; UNCLASSIFIED DRUG; VIPERIN; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; INTERLEUKIN 6; INTERLEUKIN 8; MX1 PROTEIN, HUMAN; MYXOVIRUS RESISTANCE PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN; RSAD2 PROTEIN, HUMAN;

ANTIBACTERIAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; ASTHMA; BRONCHUS MUCOSA; CELL GROWTH; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG SCREENING; EC50; EPITHELIUM CELL; ESCHERICHIA COLI; GENE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; HUMAN CELL; NONTYPEABLE HAEMOPHILUS INFLUENZAE; PROTEIN FOLDING; PSEUDOMONAS AERUGINOSA; RESPIRATORY EPITHELIUM; RESPIRATORY SYSTEM; RHINOVIRUS; STREPTOCOCCUS PNEUMONIAE; VIRUS REPLICATION; BIOSYNTHESIS; BRONCHUS; CELL CULTURE; CHEMISTRY; CYTOLOGY; DRUG DEVELOPMENT; DRUG EFFECTS; GENETICS; HAEMOPHILUS INFLUENZAE; IMMUNOLOGY; ISOLATION AND PURIFICATION; METABOLISM; PRECLINICAL STUDY;

ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIVIRAL AGENTS; ASTHMA; BRONCHI; CELLS, CULTURED; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; EPITHELIAL CELLS; ESCHERICHIA COLI; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HAEMOPHILUS INFLUENZAE; HUMANS; INTERFERON-BETA; INTERFERONS; INTERLEUKIN-6; INTERLEUKIN-8; MACROLIDES; MYXOVIRUS RESISTANCE PROTEINS; PROTEINS; PSEUDOMONAS AERUGINOSA; RHINOVIRUS; VIRUS REPLICATION;

EID: 84994792185     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkw222     Document Type: Article

References (65)

1. Kotenko SV, Gallagher G, Baurin VVet al. IFN-ls mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003; 4: 69-77.
2. Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 1957; 147: 258-67.
3. de Veer MJ, HolkoM, FrevelMet al. Functional classification of interferonstimulated genes identified using microarrays. J Leukoc Biol 2001; 69: 912-20.
4. Khabar KS, Al-Haj L, Al-Zoghaibi F et al. Expressed gene clusters associated with cellular sensitivity and resistance towards anti-viral and antiproliferative actions of interferon. J Mol Biol 2004; 342: 833-46.
5. Marcello T, Grakoui A, Barba-Spaeth G et al. Interferons a and l inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 2006; 131: 1887-98.
6. Shindo H, Maekawa S, Komase K et al. IL-28B (IFN-l3) and IFN-a synergistically inhibit HCV replication. J Viral Hepat 2013; 20: 281-9.
7. Schoggins JW, Wilson SJ, Panis M et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 2011; 472: 481-5.
8. BartlettNW, Slater L, Glanville N et al. Defining critical roles for NF-kB p65 and type I interferon in innate immunity to rhinovirus. EMBO Mol Med 2012; 4: 1244-60.
9. Chin KC, Cresswell P. Viperin (cig5), an IFN-inducible antiviral protein directly induced by human cytomegalovirus. Proc Natl Acad Sci USA 2001; 98: 15125-30.
10. Pavlovic J, Zurcher T, Haller O et al. Resistance to influenza virus and vesicular stomatitis virus conferred by expression of human MxA protein. J Virol 1990; 64: 3370-5.
11. Hinson ER, Cresswell P. The antiviral protein, viperin, localizes to lipid droplets via its N-terminal amphipathic a-helix. Proc Natl Acad Sci USA 2009; 106: 20452-7.
12. Hinson ER, Cresswell P. The N-terminal amphipathic a-helix of viperin mediates localization to the cytosolic face of the endoplasmic reticulum and inhibits protein secretion. J Biol Chem 2009; 284: 4705-12.
13. Accola MA, Huang B, Al Masri A et al. The antiviral dynamin family member, MxA, tubulates lipids and localizes to the smooth endoplasmic reticulum. J Biol Chem 2002; 277: 21829-35.
14. Zurcher T, Pavlovic J, Staeheli P. Mechanism of human MxA protein action: variants with changed antiviral properties. EMBO J 1992; 11: 1657-61.
15. Proud D, Turner RB, Winther B et al. Gene expression profiles during in vivo human rhinovirus infection: insights into the host response. Am J Respir Crit Care Med 2008; 178: 962-8.
16. Contoli M, Message SD, Laza-Stanca V et al. Role of deficient type III interferon-l production in asthma exacerbations. Nat Med 2006; 12: 1023-6.
17. Wark PA, Johnston SL, Bucchieri F et al. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. J Exp Med 2005; 201: 937-47.
18. Uller L, Leino M, Bedke N et al. Double-stranded RNA induces disproportionate expression of thymic stromal lymphopoietin versus interferon-b in bronchial epithelial cells from donors with asthma. Thorax 2010; 65: 626-32.
19. Baraldo S, Contoli M, Bazzan E et al. Deficient antiviral immune responses in childhood: distinct roles of atopy and asthma. J Allergy Clin Immunol 2012; 130: 1307-14.
20. Edwards MR, Regamey N, Vareille M et al. Impaired innate interferon induction in severe therapy resistant atopic asthmatic children. Mucosal Immunol 2012; 6: 797-806.
21. Sykes A, Edwards MR, Macintyre J et al. Rhinovirus 16-induced IFN-a and IFN-b are deficient in bronchoalveolar lavage cells in asthmatic patients. J Allergy Clin Immunol 2012; 129: 1506-14 e6.
22. Gill MA, Bajwa G, George TA et al. Counterregulation between the Fc1RI pathway and antiviral responses in human plasmacytoid dendritic cells. J Immunol 2010; 184: 5999-6006.
23. Durrani SR, Montville DJ, Pratt AS et al. Innate immune responses to rhinovirus are reduced by the high-affinity IgE receptor in allergic asthmatic children. J Allergy Clin Immunol 2012; 130: 489-95.
24. Mallia P, Message SD, Gielen V et al. Experimental rhinovirus infection as a human model of chronic obstructive pulmonary disease exacerbation. Am J Respir Crit Care Med 2010; 183: 734-42.
25. Djukanovic R, Harrison T, Johnston SL et al. The effect of inhaled IFN-b on worsening of asthma symptoms caused by viral infections. A randomized trial. Am J Respir Crit Care Med 2014; 190: 145-54.
26. Romero-Gomez M, Gonzalez-Escribano MF, Torres B et al. HLA class I B44 is associated with sustained response to interferon + ribavirin therapy in patients with chronic hepatitis C. Am J Gastroenterol 2003; 98: 1621-6.
27. Wong DK, Yim C, Naylor CD et al. Interferon alfa treatment of chronic hepatitis B: randomized trial in a predominantly homosexual male population. Gastroenterology 1995; 108: 165-71.
28. Gielen V, Johnston SL, Edwards MR. Azithromycin induces anti-viral responses in bronchial epithelial cells. Eur Respir J 2010; 36: 646-54.
29. Schogler A, Kopf BS, Edwards MR et al. Novel antiviral properties of azithromycin in cystic fibrosis airway epithelial cells. Eur Respir J 2014; 45: 428-39.
30. Papi A, Johnston SL. Rhinovirus infection induces expression of its own receptor intercellular adhesion molecule 1 (ICAM-1) via increased NF-kB-mediated transcription. J Biol Chem 1999; 274: 9707-20.
31. Sykes A, Edwards MR, Macintyre J et al. TLR3, TLR4 and TLRs7-9 induced interferons are not impaired in airway and blood cells in well controlled asthma. PLoS One 2013; 8: e65921.
32. Osterlund PI, Pietila TE, Veckman V et al. IFN regulatory factor family members differentially regulate the expression of type III IFN (IFN-l) genes. J Immunol 2007; 179: 3434-42.
33. Wang Q, Nagarkar DR, Bowman ER et al. Role of double-stranded RNA pattern recognition receptors in rhinovirus-induced airway epithelial cell responses. J Immunol 2009; 183: 6989-97.
34. Bright GM. Semi-Synthetic 4-Ureido-oleandomycin Derivatives. New York, USA: Pfizer, 1978.
35. Johnston NW, Johnston SL, Duncan JM et al. The September epidemic of asthma exacerbations in children: a search for etiology. J Allergy Clin Immunol 2005; 115: 132-8.
36. Johnston SL, Pattemore PK, Sanderson G et al. Community study of role of viral infections in exacerbations of asthma in 9-11 year old children. BMJ 1995; 310: 1225-9.
37. Message SD, Laza-Stanca V, Mallia P et al. Rhinovirus-induced lower respiratory illness is increased in asthma and related to virus load and Th1/2 cytokine and IL-10 production. Proc Natl Acad Sci USA 2008; 105: 13562-7.
38. Papi A, Bellettato CM, Braccioni F et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med 2006; 173: 1114-21.
39. Wat D, Gelder C, Hibbitts S et al. The role of respiratory viruses in cystic fibrosis. J Cyst Fibros 2008; 7: 320-8.
40. Qiu Y, Zhu J, Bandi V et al. Biopsy neutrophilia, neutrophil chemokine and receptor gene expression in severe exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003; 168: 968-75.
41. Jackson DJ, Makrinioti H, Rana BM et al. IL-33-dependent type 2 inflammation during rhinovirus-induced asthma exacerbations in vivo. Am J Respir Crit Care Med 2014; 190: 1373-82.
42. Regamey N, Tsartsali L, Hilliard TN et al. Distinct patterns of inflammation in the airway lumen and bronchial mucosa of children with cystic fibrosis. Thorax 2011; 67: 164-70.
43. Slater L, BartlettNW, Haas JJ et al. Co-ordinated role of TLR3, RIG-I and MDA5 in the innate response to rhinovirus in bronchial epithelium. PLoS Pathog 2010; 6: e1001178.
44. Wark PA, Grissell T, Davies B et al. Diversity in the bronchial epithelial cell response to infection with different rhinovirus strains. Respirology 2009; 14: 180-6.
45. Khaitov MR, Laza-Stanca V, Edwards MR et al. Respiratory virus induction of a-, b-and l-interferons in bronchial epithelial cells and peripheral blood mononuclear cells. Allergy 2009; 64: 375-86.
46. Patel DA, Patel AC, Nolan WCet al. High throughput screening for small molecule enhancers of the interferon signaling pathway to drive nextgeneration antiviral drug discovery. PLoS One 2012; 7: e36594.
47. Harrison CJ, Jenski L, Voychehovski T et al. Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection. Antiviral Res 1988; 10: 209-23.
48. Edwards L. Imiquimod in clinical practice. Australas J Dermatol 1998; 39 (Suppl 1): S14-6.
49. Thomas E, Feld JJ, Li Q et al. Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. Hepatology 2011; 53: 32-41.
50. Edwards S, Jones C, Leishman AJ et al. TLR7 stimulation of APCs results in inhibition of IL-5 through type I IFN and notch signaling pathways in human peripheral blood mononuclear cells. J Immunol 2013; 190: 2585-92.
51. Sperber SJ, Levine PA, Innes DJ et al. Tolerance and efficacy of intranasal administration of recombinant b serine interferon in healthy adults. J Infect Dis 1988; 158: 166-75.
52. Goritzka M, Durant LR, Pereira C et al. a/b Interferon receptor signaling amplifies early proinflammatory cytokine production in the lung during respiratory syncytial virus infection. J Virol 2014; 88: 6128-36.
53. Wong EH, Porter JD, Edwards MR et al. The role of macrolides in asthma: current evidence and future directions. Lancet Respir Med 2014; 2: 657-70.
54. Johnston SL, Blasi F, Black PN et al. The effect of telithromycin in acute exacerbations of asthma. N Engl J Med 2006; 354: 1589-600.
55. Albert RK, Connett J, Bailey WC et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011; 365: 689-98.
56. Yanagihara K, Izumikawa K, Higa F et al. Efficacy of azithromycin in the treatment of community-acquired pneumonia, including patients with macrolide-resistant Streptococcus pneumoniae infection. Intern Med 2009; 48: 527-35.
57. Jakobsson HE, Jernberg C, Andersson AF et al. Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome. PLoS One 2010; 5: e9836.
58. Nobel YR, Cox LM, Kirigin FF et al. Metabolic and metagenomic outcomes from early-life pulsed antibiotic treatment. Nat Commun 2015; 6: 7486.
59. Teijaro JR, Walsh KB, Rice S et al. Mapping the innate signaling cascade essential for cytokine storm during influenza virus infection. Proc Natl Acad Sci USA 2014; 111: 3799-804.
60. Wang Z, Zhang A, Wan Y et al. Early hypercytokinemia is associated with interferon-induced transmembrane protein-3 dysfunction and predictive of fatal H7N9 infection. Proc Natl Acad Sci USA 2013; 111: 769-74.
61. Hansen JL, Ippolito JA, Ban N et al. The structures of four macrolide antibiotics bound to the large ribosomal subunit. Mol Cell 2002; 10: 117-28.
62. Berisio R, Schluenzen F, Harms J et al. Structural insight into the role of the ribosomal tunnel in cellular regulation. Nat Struct Biol 2003; 10: 366-70.
63. Schlunzen F, Zarivach R, Harms J et al. Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria. Nature 2001; 413: 814-21.
64. Bulkley D, Innis CA, Blaha G et al. Revisiting the structures of several antibiotics bound to the bacterial ribosome. Proc Natl Acad Sci USA 2010; 107: 17158-63.
65. Novak P, Tatic I, Tepes P et al. Systematic approach to understanding macrolide-ribosome interactions: NMR and modeling studies of oleandomycin and its derivatives. J Phys Chem A 2006; 110: 572-9.